DH
Dr Haritha Hariprasad Nair
Also known as: Dr. Haritha H Nair
University of Florida, Rajiv Gandhi Centre for Biotechnology, OU Health Stephenson Cancer Center
Research areas: Medicine · Hepatology · Liver physiology and pathology · Cell death mechanisms and regulation · Hepatocellular Carcinoma Treatment and Prognosis
0000-0002-2957-5516
Employment
-
University of Florida Postdoctoral Associate2025 - Present
-
University of Florida Postdoctoral Associate2023 - 2025
-
Stephenson Cancer Center Postdoctoral Fellow2022 - 2023
-
Rajiv Gandhi Centre for Biotechnology Senior Research Fellow2017 - 2020
-
University of Florida Visiting fellow2017 - 2017
-
Rajiv Gandhi Centre for Biotechnology Project Fellow2016 - 2017
-
Rajiv Gandhi Centre for Biotechnology Project Fellow
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (92)
- CerS2 Is a Druggable Target in Triple-Negative Breast Cancer Save
- Data from Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis Save
- Fig. S1 from Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis Save
- Fig. S2 from Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis Save
- Fig. S3 from Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis Save
- Fig. S4 from Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis Save
- Fig. S5 from Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis Save
- Fig. S6 from Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis Save
- Fig. S7 from Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis Save
- Supplementary Data Legends from Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis Save
- Supplementary Table 1 from Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis Save
- Supplementary Table 2 from Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis Save
- Supplementary Table 3 from Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis Save
- Identification of a Novel Protein Phosphatase 2A Activator, PPA24, as a Potential Therapeutic for FOLFOX-Resistant Colorectal Cancer Save
- Data from Absence of either Ripk3 or Mlkl reduces incidence of hepatocellular carcinoma independent of liver fibrosis Save
- Fig. S1 from Absence of either Ripk3 or Mlkl reduces incidence of hepatocellular carcinoma independent of liver fibrosis Save
- Fig. S1 from Absence of either Ripk3 or Mlkl reduces incidence of hepatocellular carcinoma independent of liver fibrosis Save
- Fig. S2 from Absence of either Ripk3 or Mlkl reduces incidence of hepatocellular carcinoma independent of liver fibrosis Save
- Fig. S2 from Absence of either Ripk3 or Mlkl reduces incidence of hepatocellular carcinoma independent of liver fibrosis Save
- Fig. S3 from Absence of either Ripk3 or Mlkl reduces incidence of hepatocellular carcinoma independent of liver fibrosis Save